Saitoh Y, Mori S, Arita N, Hayakawa T, Mogami H, Matsumoto K, Mori H
Cancer Res. 1986 Mar;46(3):1507-12.
To ascertain the mechanisms of bromocriptine in lowering serum prolactin (PRL) levels and reducing the cell size of human prolactinomas, stereological analysis at electron microscope level was performed on six adenomas treated with bromocriptine (10 mg/day for 2 weeks) and four untreated adenomas. The bromocriptine treatment significantly decreased all the major organelles involved in PRL synthesis when expressed in absolute volume per single tumor cell, although it decreased only Golgi apparatus when expressed in relative volume within the cells. Secretory granules, lysosomes, and lipid droplets increased in relative volume but not in absolute volume in bromocriptine-treated adenomas. Consequently, bromocriptine decreased the volume of individual tumor cell to approximately 60% of that of untreated tumor cells. Unexpectedly, exocytosis of secretory granules increased significantly in the bromocriptine-treated adenomas in spite of a remarkable decrease in serum PRL levels. This appears to be contradictory to the current view that a decrease in serum PRL levels with a concurrent increase in the intracellular PRL levels caused by bromocriptine treatment results from the inhibition of exocytosis of secretory granules. The secretory granules of bromocriptine-treated adenomas may contain a small amount of PRL, as suggested by a culture study reporting degradation of PRL by bromocriptine.
为确定溴隐亭降低血清催乳素（PRL）水平及减小人催乳素瘤细胞大小的机制，对6例接受溴隐亭治疗（10毫克/天，共2周）的腺瘤及4例未治疗的腺瘤进行了电子显微镜水平的体视学分析。当以单个肿瘤细胞的绝对体积表示时，溴隐亭治疗显著减少了所有参与PRL合成的主要细胞器，尽管以细胞内相对体积表示时仅高尔基体减少。在溴隐亭治疗的腺瘤中，分泌颗粒、溶酶体和脂滴的相对体积增加，但绝对体积未增加。因此，溴隐亭将单个肿瘤细胞的体积减小至未治疗肿瘤细胞的约60%。出乎意料的是，尽管血清PRL水平显著降低，但溴隐亭治疗的腺瘤中分泌颗粒的胞吐作用显著增加。这似乎与当前观点相矛盾，即溴隐亭治疗导致血清PRL水平降低同时细胞内PRL水平升高是由于分泌颗粒胞吐作用受到抑制。如一项培养研究报告溴隐亭可降解PRL所提示的，溴隐亭治疗的腺瘤的分泌颗粒可能含有少量PRL。
